Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CAR-T Win: Bluebird Bio Announces Positive Phase I Clinical Trial Results

XTALKS VITALS NEWS

CAR-T

So far, bluebird hasn’t reported any serious adverse events related to bb2121, which is being developed alongside pharmaceutical company, Celgene.

Share this!

December 2, 2016 | by Sarah Hand, M.Sc.

Earlier this week, biotech company bluebird bio released positive interim results from their Phase I clinical trial of CAR-T immunotherapy, in patients with relapsed or refractory multiple myeloma. The dose escalation study showed a 78 percent overall response rate for its investigational anti-B-cell maturation antigen (BCMA), known as bb2121.

“We are pleased that these early data from our ongoing Phase 1 study of bb2121 demonstrate objective anti-tumor responses in heavily pre-treated patients with multiple myeloma,” said Dr. David Davidson, chief medical officer, bluebird bio. “We are also encouraged by the safety profile to date, particularly the lack of severe cytokine release syndrome or neurotoxicity.”



Last week, bluebird’s competitor in the immunotherapy space, Juno Therapeutics, announced that two patients in its CAR-T clinical trial died as a result of a potentially treatment-related adverse event. The deaths prompted Juno to put a hold on the trial for the second time since its launch, and increased the number of CAR-T associated fatalities to six patients.

Earlier this year, the US Food and Drug Administration (FDA) mandated a clinical hold on Juno’s Phase II clinical trial – ROCKET – after two patients died of cerebral edema. Less than one week after the study was put on hold, the FDA allowed the trial to continue after changes were made to the treatment protocol.

So far, bluebird hasn’t reported any serious adverse events related to bb2121, which is being developed alongside pharmaceutical company, Celgene. While bluebird’s CAR-T cell product has shown promising efficacy in interim trial results, the study is still ongoing.

“In light of these positive data,” continued Davidson, “and thanks to the multiple participating clinical sites and centralized manufacturing infrastructure we and our partner Celgene have built for this program, we anticipate efficiently completing the dose escalation stage of the trial and initiating the expansion cohort.”


Keywords: CAR-T, Clinical Trial, Immunotherapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.